Abstract
The results of treatment for early stage recurrent hepatocellular carcinoma (HCC) remain controversial. This study aimed to analyze the clinical outcomes of recurrent HCC within the Milan criteria following different treatment modalities except liver transplantation. From January 2006 to December 2016, 272 consecutive HCC patients who developed intrahepatic recurrence after hepatectomy that satisfied the Milan criteria and Child–Pugh class A or B liver function were retrospectively enrolled. The outcomes of repeat resection (RR), local ablative therapy (LAT), or transarterial chemoembolization (TACE) were reported, and the prognostic factors of survival were investigated. Among the 272 patients, 136 (50.0%), 71 (26.1%), and 65 (23.9%) received TACE, LAT, and RR treatments, respectively. Treatment-related complications were 9.5%, 11.3%, and 10.7%, respectively, in the three groups. No patient died of treatment-related complication. The 1-, 3-, and 5-year overall survival rates after recurrence were 95.0%, 54.2%, and 45.8%, respectively, in the RR group; 86.6%, 51.7%, and 42.4%, respectively, in the LAT group; and 77.2%, 46.5%, and 38.4%, respectively, in the TACE group. On multivariate analysis, three independent factors related to survival after recurrences were identified. A single tumor nodule and AFP < 200 ng/mL predicted better survival, while a disease-free interval ≤ 1 year was associated with poor outcomes. RR and LAT could achieve good survival outcomes in well-selected patients with recurrent HCC within the Milan criteria, while TACE was the main form of treatment when curative therapy was not considered feasible and the clinical outcomes were satisfactory.
Similar content being viewed by others
Data Availability
Clinical data of the patients is attached as the supplementary material.
Code Availability
Not applicable.
References
Zhong JH, Ke Y, Gong WF et al (2014) Hepatic resection associated with good survival for selected patients with intermediate and advanced-stage hepatocellular carcinoma. Ann Surg 260:329–340
Chan DL, Alzahrani NA, Morris DL et al (2014) Systematic review of efficacy and outcomes of salvage liver transplantation after primary hepatic resection for hepatocellular carcinoma. J Gastroenterol Hepatol 29:31–41
Guo Y, Tan EK, Krishnamoorthy TL et al (2019) Outcomes of salvage liver transplant for recurrent hepatocellular carcinoma: a comparison with primary liver transplant. Ann Hepatobiliary Pancreat Surg 23:1–7
Hu Z, Wang W, Li Z et al (2012) Recipient outcomes of salvage liver transplantation versus primary liver transplantation: a systematic review and meta-analysis. Liver Transpl 18:1316–1323
Lim C, Shinkawa H, Hasegawa K et al (2017) Salvage liver transplantation or repeat hepatectomy for recurrent hepatocellular carcinoma: an intent-to-treat analysis. Liver Transpl 23:1553–1563
Wang HL, Mo DC, Zhong JH et al (2019) Systematic review of treatment strategy for recurrent hepatocellular carcinoma. Salvage liver transplantation or curative locoregional therapy. Medicine (Baltimore) 98:e14498
Fuks D, Dokmak S, Paradis V et al (2012) Benefit of initial resection of hepatocellular carcinoma followed by transplantation in case of recurrence: an intention-to-treat analysis. Hepatology 55:132–140
Liu F, Wei Y, Wang W et al (2012) Salvage liver transplantation for recurrent hepatocellular carcinoma within UCSF criteria after liver resection. PLOS ONE 7:e48932
Wu L, Hu A, Tam N et al (2012) Salvage liver transplantation for patients with recurrent hepatocellular carcinoma after curative resection. PLOS ONE 7:e41820
Wen T, Jin C, Facciorusso A et al (2018) Multidisciplinary management of recurrent and metastatic hepatocellular carcinoma after resection: an international expert consensus. Hepatobiliary Surg Nutr 7:353–371
Yagi R, Midorikawa Y, Moriguchi M et al (2018) Liver resection for recurrent hepatocellular carcinoma to improve survivability: a proposal of indication criteria. Surgery 163:1250–1256
Meniconi RL, Komatsu S, Perdigao F et al (2015) Recurrent hepatocellular carcinoma: a Western strategy that emphasizes the impact of pathologic profile of the first resection. Surgery 157:454–462
Li M, Wang Z, Cao J et al (2019) Risk factors and prognosis of patients with recurrent hepatocellular carcinoma who undergo liver re-resections. Eur J Surg Oncol 45:1684–1690
Chan AC, Poon RT, Cheung TT et al (2012) Survival analysis of re-resection versus radiofrequency ablation for intrahepatic recurrence after hepatectomy for hepatocellular carcinoma. World J Surg 36:151–156
Liang HH, Chen MS, Peng ZW et al (2008) Percutaneous radiofrequency ablation versus repeat hepatectomy for recurrent hepatocellular carcinoma: a retrospective study. Ann Surg Oncol 15:3484–3493
Song KD, Lim HK, Rhim H et al (2015) Repeated hepatic resection versus radiofrequency ablation for recurrent hepatocellular carcinoma after hepatic resection: a propensity score matching study. Radiology 275:599–608
Jin YJ, Lee JW, Lee OH et al (2014) Transarterial chemoembolization versus surgery/radiofrequency ablation for recurrent hepatocellular carcinoma with or without microvascular invasion. J Gastroenterol Hepatol 29:1056–1064
Koh PS, Chan ACY, Cheung TT et al (2016) Efficacy of radiofrequency ablation compared with transarterial chemoembolization for the treatment of recurrent hepatocellular carcinoma: a comparative survival analysis. HPB (Oxf) 18:72–78
Xiao H, Chen ZB, Jin HL et al (2019) Treatment selection of recurrent hepatocellular carcinoma with microvascular invasion at the initial hepatectomy. Am J Transl Res 11:1864–1875
Lee JM, Yoon JH, Joo I et al (2012) Recent advances in CT and MR imaging for evaluation of hepatocellular carcinoma. Liver Cancer 1:22–40
Kircher A, Bongartz G, Merkle EM et al (2014) Rational imaging of hepatocellular carcinoma: the challenge of multimodal diagnostic criteria. Radiologe 54:664–672
Bruix J, Sherman M (2011) American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 53:1020–1022
Guo WX, Zhai B, Lai EC et al (2010) Percutaneous radiofrequency ablation versus partial hepatectomy for multicentric small hepatocellular carcinomas: a nonrandomized comparative study. World J Surg 34:2671–2676
Author information
Authors and Affiliations
Contributions
All the authors contributed to the study conception and design. Material preparation, data collection, and analysis were performed by Xiaoliang Yang, Xingwu Zhu, and Maixuan Qiu. The first draft of the manuscript was written by Jing Li and Liang Huang, and all the authors commented on the previous versions of the manuscript. All the authors read and approved the final manuscript.
Corresponding author
Ethics declarations
Conflict of Interest
The authors declare no competing interests.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Li, J., Yang, X., Huang, L. et al. Treatment Strategy for Post-hepatectomy Recurrent Hepatocellular Carcinoma Within the Milan Criteria: Repeat Resection, Local Ablative Therapy or Transarterial Chemoembolization?. Indian J Surg 84 (Suppl 2), 384–389 (2022). https://doi.org/10.1007/s12262-022-03343-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12262-022-03343-1